News Media Attacks Vitamin C Treatment of COVID-19 Coronavirus

FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, Mar 1, 2020

News Media Attacks Vitamin C Treatment of COVID-19 Coronavirus

Yet Ascorbate is a Proven, Powerful Antiviral

by Andrew W. Saul, Editor-in-Chief

(OMNS Mar 1, 2020) First of all, the naysayers are too late. Vitamin C is already being used to prevent and treat COVID-19 in China and in Korea. And it is working.

Here is a verified official statement from China's Xi'an Jiaotong University Second Hospital:

"On the afternoon of February 20, 2020, another 4 patients with severe coronavirus pneumonia recovered from the C10 West Ward of Tongji Hospital. In the past 8 patients have been discharged from hospital. . . [H]igh-dose vitamin C achieved good results in clinical applications. We believe that for patients with severe neonatal pneumonia, and for critically ill patients, vitamin C treatment should be initiated as soon as possible after admission. Numerous studies have shown that the dose of vitamin C has a lot to do with the effect of treatment. High-dose vitamin C can not only improve antiviral levels, but more importantly, can prevent and treat acute lung injury (ALI) and acute respiratory distress (ARDS)."

Here is a report from Korea:

"At my hospital in Daegu, South Korea, all inpatients and all staff members have been using vitamin C orally since last week. Some people this week had a mild fever, headaches and coughs, and those who had symptoms got 30,000 mg intravenous vitamin C. Some people got better after about two days, and most had symptoms go away after one injection." (Hyoungjoo Shin, M.D.)

There are at least three high-dose intravenous vitamin C studies underway in China. Literally by the truckload, tons of vitamin C has been sent into Wuhan.

Here is a report from a physician in China:

"We need to broadcast a message worldwide very quickly: Vitamin C (small or large dose) does no harm to people and is the one of the few, if not the only, agent that has a chance to prevent us from getting, and can treat, COVID-19 infection. When can we, medical doctors and scientists, put patients' lives first?" (Richard Z. Cheng, MD, PhD, International Vitamin C China Epidemic Medical Support Team Leader)

News media attacks on vitamin C are centered on false allegations of dangers with megadoses. This tactic lets the media ignore the truth that even LOW doses of vitamin C reduce symptoms and death rates. Do not let the media spin this issue. Advocates of vitamin C are medical doctors, not spin doctors. They are experienced, credentialed clinicians who have read the science, a small sample of which follows:

Even small supplemental amounts of vitamin C can keep severely ill patients from dying.
[Hunt C et al. Int J Vitam Nutr Res 1994;64:212-19.]

Infants with viral pneumonia treated with vitamin C had reduced mortality.
[Ren Shiguang et al. Hebei Medicine 1978,4:1-3]

Moderate doses of vitamin C shortened ICU stay by 97% in a subgroup of 1,766 patients
[Hemilä H, Chalker E. Nutrients. 2019 Mar 27;11:4.]

200 mg of vitamin C reduced duration of severe pneumonia in children. Oxygen saturation was improved in less than one day.
[Khan IM et al. J Rawalpindi Med Coll (JRMC); 2014;18(1):55-57]

The Orthomolecular Medicine News Service, and its editorial board of nearly four dozen physicians, academics and health professionals (listed below) feel it is necessary to report on what the advertiser-supported, corporate-controlled commercial media refuses to acknowledge: even small amounts of vitamin C dramatically decrease severity of symptoms, and increase survival rates, among severely ill viral patients. Large doses work better. Intravenous large doses work better still.

OMNS has been relentlessly reporting on this for weeks:

Feb 28, 2020

Vitamin C and COVID-19 Coronavirus

Feb 23, 2020

TONS OF VITAMIN C TO WUHAN: China Using Vitamin C against COVID

Feb 21, 2020

Three Intravenous Vitamin C Research Studies Approved for Treating COVID-19

Feb 16, 2020

Early Large Dose Intravenous Vitamin C is the Treatment of Choice for 2019-nCov Pneumonia

Feb 13, 2020

Coronavirus Patients in China to be Treated with High-Dose Vitamin C

Feb 10, 2020

VITAMIN C AND ITS APPLICATION TO THE TREATMENT OF nCoV CORONAVIRUS: How Vitamin C Reduces Severity and Deaths from Serious Viral Respiratory Diseases

Feb 2, 2020

Hospital-based Intravenous Vitamin C Treatment for Coronavirus and Related Illnesses

Jan 30, 2020

Nutritional Treatment of Coronavirus

Jan 26, 2020

Vitamin C Protects Against Coronavirus

 

The greatest danger with COVID-19 coronavirus is illness progression to SARS (Severe Acute Respiratory Syndrome) and pneumonia. Physicians have successfully used vitamin C against viral pneumonia since the 1940s. That's the point made in a 10-minute video that was abruptly removed from YouTube, supposedly for being a violation of their "community standards": https://www.brighteon.com/646ad120-775a-4464-a0d1-609be7a0a9dc

OMNS favors a community of people of all nations dedicated to immediately employing all existing, science-based measures to stop a dreaded disease for which there is no conventional cure. Vitamin C is available now. It is not new. And it is not "unproven." Vitamin C has been used as an antiviral since the 1930s. (1) It has been used in very high injected doses since the 1940s. (2) In the decades since, vitamin C has been used for influenza, SARS and viral pneumonia. (3)

"Vitamin C can truthfully be designated as the antitoxic and antiviral vitamin."
(Claus W. Jungeblut, M.D., Professor, Columbia University College of Physicians and Surgeons)

All OMNS releases are duly referenced to the research literature. Yet if you post what you are reading now on Facebook, it is likely to be blocked or labeled "false information." Since when is reviewing the medical literature "fake news"?

It is our editorial viewpoint that withholding vitamin C treatment information from the public withholds it from the patient.

We accuse the media of negligence. They can correct this any time.

Until they do, we will do it for them.

 

References

(1) Jungeblut CW. Inactivation of poliomyelitis virus by crystalline vitamin C (ascorbic acid). J Exper Med 1935. 62:317-321.

Jungeblut CW. Vitamin C therapy and prophylaxis in experimental poliomyelitis. J Exp Med, 1937. 65: 127-146.

Jungeblut CW. Further observations on vitamin C therapy in experimental poliomyelitis. J Exper Med, 1937. 66: 459-477.

Jungeblut CW, Feiner RR. Vitamin C content of monkey tissues in experimental poliomyelitis. J Exper Med, 1937. 66: 479-491.

Jungeblut CW. A further contribution to vitamin C therapy in experimental poliomyelitis. J Exper Med, 1939. 70:315-332.

Saul AW. Taking the cure: Claus Washington Jungeblut, M.D.: Polio pioneer; ascorbate advocate. J Orthomolecular Med, 2006. Vol 21, No 2, p 102-106. http://www.doctoryourself.com/jungeblut.html and http://orthomolecular.org/library/jom

(2) http://orthomolecular.org/resources/omns/v16n09.shtml and http://www.orthomolecular.org/resources/omns/v09n16.shtml Frederick Robert Klenner's papers are listed and summarized in Clinical Guide to the Use of Vitamin C (ed. Lendon H. Smith, MD, Life Sciences Press, Tacoma, WA, 1988. This book is posted for free access at http://www.seanet.com/~alexs/ascorbate/198x/smith-lh-clinical_guide_1988.htm

(3) Cathcart RF. (1981) Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. Med Hypotheses. 7:1359-76. http://www.doctoryourself.com/titration.html

Cathcart RF. (1993) The third face of vitamin C. J Orthomolecular Med, 7:197-200. Free access at http://www.doctoryourself.com/cathcart_thirdface.html

Additional Dr. Cathcart papers are posted at http://www.doctoryourself.com/biblio_cathcart.html

 

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

 

Editorial Review Board:

Ilyès Baghli, M.D. (Algeria)
Ian Brighthope, MBBS, FACNEM (Australia)
Prof. Gilbert Henri Crussol (Spain)
Carolyn Dean, M.D., N.D. (USA)
Damien Downing, M.D. (United Kingdom)
Michael Ellis, M.D. (Australia)
Martin P. Gallagher, M.D., D.C. (USA)
Michael J. Gonzalez, N.M.D., D.Sc., Ph.D. (Puerto Rico)
William B. Grant, Ph.D. (USA)
Tonya S. Heyman, M.D. (USA)
Suzanne Humphries, M.D. (USA)
Ron Hunninghake, M.D. (USA)
Robert E. Jenkins, D.C. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Jeffrey J. Kotulski, D.O. (USA)
Peter H. Lauda, M.D. (Austria)
Thomas Levy, M.D., J.D. (USA)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Charles C. Mary, Jr., M.D. (USA)
Mignonne Mary, M.D. (USA)
Jun Matsuyama, M.D., Ph.D. (Japan)
Dave McCarthy, M.D. (USA)
Joseph Mercola, D.O. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Tahar Naili, M.D. (Algeria)
W. Todd Penberthy, Ph.D. (USA)
Dag Viljen Poleszynski, Ph.D. (Norway)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Hyoungjoo Shin, M.D. (South Korea)
Thomas L. Taxman, M.D. (USA)
Jagan Nathan Vamanan, M.D. (India)
Garry Vickar, MD (USA)
Ken Walker, M.D. (Canada)
Anne Zauderer, D.C. (USA)

 

Andrew W. Saul, Ph.D. (USA), Editor-In-Chief
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Robert G. Smith, Ph.D. (USA), Associate Editor
Helen Saul Case, M.S. (USA), Assistant Editor
Michael S. Stewart, B.Sc.C.S. (USA), Technology Editor
Jason M. Saul, JD (USA), Legal Consultant